MD3: THE IMPACT OF REQUIRING A FIXED PERIOD OF ELIGIBILITY IN ECONOMIC AND EPIDEMIOLOGICAL STUDIES THAT UTILIZE LONGITUDINAL DATA

Autor: Eaton, SC, McQuay, LJ, Clark, DW, Paul, JE, Hauber, AB

Publikováno v: In Value in Health 2003 6(3):179-180

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program.

Autor: de Vogel S; Pharmacovigilance, Astellas Pharma B.V., Leiden, The Netherlands., Seeger JD; Epidemiology, Optum, Boston, Massachusetts, USA., Arana A; Epidemiology, RTI Health Solutions, Barcelona, Spain., Margulis AV; Epidemiology, RTI Health Solutions, Barcelona, Spain., McQuay LJ; Epidemiology, RTI Health Solutions, Research Triangle Park, Durham, North Carolina, USA., Perez-Gutthann S; Epidemiology, RTI Health Solutions, Barcelona, Spain., Hallas J; Public Health, University of Southern Denmark, Odense, Denmark., Kristiansen NS; Public Health, University of Southern Denmark, Odense, Denmark., Linder M; Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, Sweden., Odsbu I; Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, Sweden., Suehs B; Health Economics and Outcomes Research, Humana Healthcare Research, Louisville, Kentucky, USA., Xu Y; Health Economics and Outcomes Research, Humana Healthcare Research, Louisville, Kentucky, USA., Uribe C; Health Economics and Outcomes Research, Humana Healthcare Research, Louisville, Kentucky, USA., Appenteng K; Pharmacovigilance, Astellas Pharma US, Northbrook, Illinois, USA., Robinson NJ; Pharmacovigilance, Astellas Pharma B.V., Leiden, The Netherlands.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 May; Vol. 33 (5), pp. e5799.

Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States.

Autor: Forns J; Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain. jforns@rti.org., Danysh HE; Pharmacoepidemiology and Risk Management, RTI Health Solutions, Waltham, MA, USA., McQuay LJ; Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA., Turner ME; Drug Safety and Pharmacovigilance, ACADIA Pharmaceuticals Inc, Princeton, NJ, USA., Dempsey C; Drug Safety and Pharmacovigilance, ACADIA Pharmaceuticals Inc, Princeton, NJ, USA., Anthony MS; Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA., Demos G; Drug Safety and Pharmacovigilance, ACADIA Pharmaceuticals Inc, San Diego, CA, USA., Layton JB; Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.

Publikováno v: BMC geriatrics [BMC Geriatr] 2022 Oct 06; Vol. 22 (1), pp. 784. Date of Electronic Publication: 2022 Oct 06.